Irritable bowel syndrome in view of the rome IV criteria (2016)
https://doi.org/10.21518/2079-701X-2018-3-60-66
Abstract
The review article reflects a contemporary view of irritable bowel syndrome (IBS) based on the Rome IV Criteria (2016). The paper studies the matters of definition, classification, features of the clinical picture and diagnostic criteria for IBS. It outlines the real-time findings of the pharmacotherapy of IBS from the perspective of evidence-based medicine.
About the Authors
D. T. Dicheva
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
D. N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
M. P. Scheglanova
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
Russian Federation
E. V. Partsvania-Vinogradova
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology, 2016, 150: 1393–1407.
2. Lacy BE, Patel NK. Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J Clin Med, 2017, 6(11). pii: E99.
3. Samsonov AA, Andreev DN, Dicheva DT. Irritable bowel syndrome from the perspective of modern gastroenterology. Farmateka, 2014, 18: 7-14
4. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther, 2014, 40(9): 1023-34.
5. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol, 2014, 6: 71-80.
6. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol, 2012, 10: 712–721.
7. Maev IV, Dicheva DT, Andreev DN, Senina YuS. Irritable bowel syndrome in the practice of a gastroenterologist. In collected works: Current issues of departmental medicine. M., 2012: 83-8
8. Ford AC, Forman D, Bailey AG et al. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008, 103: 1229–1239.
9. Halder SL, Locke GR 3rd, Schleck CD et al. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology, 2007, 133: 799–807.
10. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology, 1991, 100: 998.
11. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology, 2016, 150(6): 1257-61.
12. Maev IV, Cheremushkin SV, Kucheryavy YuA. Irritable bowel syndrome. Rome IV criteria. On the role of visceral hypersensitivity and ways of its correction. Guidance manual. M., 2016.
13. Andreev DN, Zaborovsky AV, Trukhmanov AS, et al. Evolution of ideas about functional diseases of the gastrointestinal tract in view of the revised Rome IV criteria (2016). RJGGK, 2017, 1: 4-11
14. Spiegel BM, Bolus R, Agarwal N et al. Measuring symptoms in the irritable bowel syndrome: development of a framework for clinical trials. Aliment Pharmacol Ther, 2010, 32: 1275–1291.
15. Palsson O, Heymen S, Whitehead WE. Abdominal pain versus abdominal discomfort: implications for diagnostic assessment of irritable bowel syndrome (IBS). United Eur Gastroenterol J, 2014, 2: P405.
16. Begtrup LM, Engsbro AL, Kjeldsen J et al.A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol, 2013, 11: 956–962.
17. Andreev DN, Samsonov AA, Cheremushkin SV. Irritable bowel syndrome: diagnostic criteria and approaches to therapy. Farmateka, 2014, 14: 6-11
18. Guidelines for Internal Medicine. Edited by Arutyunova GP, Martynova AI, Spassky AA. Moscow, 2015.
19. Maev IV, Kucheryavyy YuA, Andreev DN. Functional dyspepsia: epidemiology, classification, etiopathogenesis, diagnosis and treatment: scientific dossier. M.: ST-Print, 2015.
20. Maev IV, Dicheva DT, Scheglanova MP. Functional dyspepsia in view of the revised Rome IV criteria (2016). Gastroenterology. Appendix to the Journal Consilium Medicum, 2016, 2: 5-10
21. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol, 2010, 8: 401-9.
22. Riegler G, Esposito I. Bristol scale stool form.A still valid help in medical practice and clinical research. Tech Coloproctol, 2001, 5(3): 163-4.
23. Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther, 2012, 35: 350–359.
24. Vandvik PO, Wilhelmsen I, Ihlebaek C et al. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical impli cations. Aliment Pharmacol Ther, 2004, 20: 1195–1203.
25. Whitehead WE, Palsson OS, Levy RR et al. Comorbidity in irritable bowel syndrome. Am J Gastroenterol, 2007, 102: 2767–2776.
26. Ford AC, BercikP, Morgan DG et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology, 2013, 145: 1262–1270.
27. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA, 2008, 300: 1793–1805.
28. Menees ST, Kurlander J, Goel A et al. Meta-analysis of the utility of common serum and fecal biomarkers in adults with IBS. Gastroenterology, 2014, 146(Suppl): S194.
29. Waugh N, Cummins E, Royle P et al. Faecal cal-protectin testing for differentiating amongst inflammatory and noninflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess, 2013, 17: 1–211.
30. Ghoshal UC, Srivastava D, Verma A et al. Tropical sprue in 2014: the new face of an old disease. Curr Gastroenterol Rep, 2014, 16: 391.
31. Yushchuk ND, Andreev DN, Kucheryavyy YuA. Acute diarrhea in adults: the urgency of the problem and the new possibilities of therapy. Infektsionnye bolezni: novosti, mneniya, obuchenie, 2017, 4 (21): 99-107
32. Maev IV, Kucheryavy YuA, Andreev DN, Cheryomushkin SV. Evolution of concepts for microscopic colitis. Terapevticheskiy arkhiv, 2015, 87 (4): 69-76
33. Slattery SA, Niaz O, Azia Q et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther, 2015, 42: 3–11.
34. Maev IV, Cheremushkin SV, Kucheryavy YuA, Cheremushkina NV. Irritable bowel syndrome. Rome IV criteria. Consilium Medicum, 2016, 8: 79-85.
35. Andreev DN, Dicheva DT. Modern non-pharmacological and pharmacotherapeutic approaches to the treatment of irritable bowel syndrome. Gastroentero logy. Appendix to the Journal Consilium Medicum, 2014, 2: 47-52./
36. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann. Intern. Med., 1995, 122: 107.
37. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med, 1999, 107: 41–50.
38. Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology, 1988, 95: 701–708.
39. Johannesson E, Simrén M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol, 2011, 106: 915–922.
40. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol, 2014, 109(Suppl 1): 2–27.
41. Hirshkowitz M, Whiton K, Albert SM et al. National Sleep Foundation’s sleep time duration recommendations: methodology and results summary. Sleep Health, 2015 Mar, 1(1): 40-43.
42. Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebocontrolled trial. Am J Gastroenterol, 2011, 106: 508–514.
43. Vazquez-Roque MI, Camilleri M, Smyrk T et al.Acontrolled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology, 2013, 144: 903–911.
44. Kazyulin AN, Dicheva DT, Russ IS, Andreev DN, Partzvania-Vinogradova EV. Dietotherapy with reduced content of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (fodmap) in irritable bowel syndrome. Consilium Medicum, 2016, 18 (8): 75-78.
45. Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am. J. Gastroenterol., 2013, 108: 707.
46. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y), 2012, 8(11): 739-45.
47. Staudacher HM, Irving PM, Lomer MC, Whelan K. Mechanisms and efficacy of dietary FODMAP restriction in IBS. Nat Rev Gastroenterol Hepatol, 2014, 11(4): 256-66.
48. Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr, 2012, 142(8): 1510-8.
49. Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol, 2010 Aug, 25(8): 1366-73.
50. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 2014, 146: 67.
51. Federal guidelines on the use of medicinal products (formulary system). Issue XVIII. Moscow: Vidoks, 2017
52. Poynard T, Regimbeau C, Benhamou Y. Metaanalysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther, 2001 Mar, 15(3): 355-61.
53. Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA et al. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis. Rev Gastroenterol Mex, 2012 Apr-Jun, 77(2): 82-90.
54. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic re view and meta-analysis. BMJ, 2008 Nov 13, 337: a2313.
55. Maev IV, Samsonov AA, Andreev DN. A modern algorithm for managing patients with chronic constipation syndrome from the perspective of introducing new pharmacological agents. Farmateka, 2012, 13: 37-43
56. Kucheryavy YuA, Andreev DN, Cheremushkin SV. Chronic constipation: urgency, problems and modern treatment options. Consilium Medicum, 2017, 19 (8): 116-120.
57. Maev I., Dicheva D., Andreev D. New possibilities of treatment of chronic constipation. Vrach, 2012, 3: 45-8
58. Lavo B, Stenstam M, Nielsen AL et al. Loperamide in treatment of irritable bowel syndrome— a double-blind placebo controlled study. Scand J Gastroenterol Suppl, 1987, 130: 77–80.
59. Laterza L, Ianiro G, Scoleri I et al. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother, 2015 Mar, 16(4): 607-15.
60. Calanni F, Renzulli C, Barbanti M, Viscomi GC. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo), 2014 Sep, 67(9): 667-70.
61. Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep, 2015, 5: 12693.
62. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J. Gastroenterol, 2014, 20(10): 2456–69.
63. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther, 2017 Mar, 45(5): 604-616.
64. Li J, Zhu W, Liu W, Wu Y, Wu B. Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials. Medicine (Baltimore), 2016 Jan, 95(4): e2534.
65. Schoenfeld P, Pimentel M, Chang L et al. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther, 2014 May, 39(10): 1161-8.
66. Ivashkin VT, Shelygin YuA, Baranskaya EK. et al. Clinical guidelines of the Russian Gastroenterological Association and the Association of Coloproctologists of Russia on the Diagnosis and Treat ment of Irritable Bowel Syndrome. Ros. zhurn. gastroenterol. gepatol. koloproktol, 2017, 27 (5): 76-93.
67. Sebastián Domingo JJ. Review of the role of pro-biotics in gastrointestinal diseases in adults. Gastroenterol Hepatol, 2017, 40(6): 417-429.
68. Zhang Y, Li L, Guo C et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol, 2016, 16(1): 62.
Review
For citations:
Dicheva DT, Andreev DN, Scheglanova MP, Partsvania-Vinogradova EV. Irritable bowel syndrome in view of the rome IV criteria (2016). Meditsinskiy sovet = Medical Council. 2018;(3):60-66. (In Russ.) https://doi.org/10.21518/2079-701X-2018-3-60-66
Views:
1607
Email this article 